Intravenous application of CD271-selected mesenchymal stem cells during fracture healing.

MedStar author(s):
Citation: J Orthop Trauma. 28 Suppl 1:S15-9, 2014.Journal of Orthopaedic Trauma. 28 Suppl 1:S15-9, 2014.PMID: 24378433Institution: MedStar Union Memorial HospitalDepartment: Orthobiologic Laboratory | Orthopaedic SurgeryForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, N.I.H., Extramural | Research Support, Non-U.S. Gov'tSubject headings: *Femoral Fractures/pp [Physiopathology] | *Femoral Fractures/th [Therapy] | *Fracture Healing/ph [Physiology] | *Mesenchymal Stem Cell Transplantation | *Mesenchymal Stromal Cells/ph [Physiology] | Adapalene | Animals | Carrier Proteins/pd [Pharmacology] | Cell Movement/de [Drug Effects] | Disease Models, Animal | Immunohistochemistry | In Vitro Techniques | Injections, Intravenous | Male | Mesenchymal Stromal Cells/de [Drug Effects] | Mice | Naphthalenes | Spectroscopy, Near-InfraredYear: 2014Local holdings: Available online from MWHC library: 1996 - presentISSN:
  • 0890-5339
Name of journal: Journal of orthopaedic traumaAbstract: CLINICAL RELEVANCE: Intravenous application of MSCs may serve as a practical route to deliver stem cells for the treatment of fracture nonunion and delayed union.CONCLUSIONS: After intravenous injection, CD271-selected MSCs were recruited to the fracture sites. The stages of fracture healing influenced the homing of culture-expanded MSCs. In mice, an optimal window of intravenous injection of MSCs was around 24 hours after fracture.METHODS: Based on the expression of CD271, MSCs were isolated from human bone marrow and labeled with cypate, a near-infrared fluorochrome. A unilateral closed fracture was created at the femur in immunodeficient mice. The cypate-labeled MSCs were injected into the tail vein of the mice at days 1 and 3 after fracture and were tracked by near-infrared imaging. The mice were euthanized at 3 weeks after fracture. Immunohistochemistry was performed to detect human MSCs at the fracture sites. Migration of CD271-selected MSCs, under the influence of stem cell-derived factor-1, was assessed in vitro.OBJECTIVES: Circulating mesenchymal stem cells (MSCs) participate in fracture healing and can be used to enhance fracture healing. This study investigated how CD271-selected MSCs travel in circulation and when is the optimal time to apply MSCs intravenously during fracture healing.RESULTS: Intravenously injected at day 1, but not day 3, after fracture, CD271-selected MSCs accumulated at the fracture sites significantly and lasted for at least 7 days. All fractures, with or without MSC injections, healed in 3 weeks. Human cells were localized at the fracture sites in mice by immunohistochemistry. CD271-selected MSCs migrated toward the medium contained stem cell-derived factor-1 in vitro.All authors: Achilefu S, Akers W, Dreger T, Molligan J, Schon LC, Watson JT, Zhang ZFiscal year: FY2015Digital Object Identifier: Date added to catalog: 2016-07-15
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 24378433 Available 24378433

Available online from MWHC library: 1996 - present

CLINICAL RELEVANCE: Intravenous application of MSCs may serve as a practical route to deliver stem cells for the treatment of fracture nonunion and delayed union.

CONCLUSIONS: After intravenous injection, CD271-selected MSCs were recruited to the fracture sites. The stages of fracture healing influenced the homing of culture-expanded MSCs. In mice, an optimal window of intravenous injection of MSCs was around 24 hours after fracture.

METHODS: Based on the expression of CD271, MSCs were isolated from human bone marrow and labeled with cypate, a near-infrared fluorochrome. A unilateral closed fracture was created at the femur in immunodeficient mice. The cypate-labeled MSCs were injected into the tail vein of the mice at days 1 and 3 after fracture and were tracked by near-infrared imaging. The mice were euthanized at 3 weeks after fracture. Immunohistochemistry was performed to detect human MSCs at the fracture sites. Migration of CD271-selected MSCs, under the influence of stem cell-derived factor-1, was assessed in vitro.

OBJECTIVES: Circulating mesenchymal stem cells (MSCs) participate in fracture healing and can be used to enhance fracture healing. This study investigated how CD271-selected MSCs travel in circulation and when is the optimal time to apply MSCs intravenously during fracture healing.

RESULTS: Intravenously injected at day 1, but not day 3, after fracture, CD271-selected MSCs accumulated at the fracture sites significantly and lasted for at least 7 days. All fractures, with or without MSC injections, healed in 3 weeks. Human cells were localized at the fracture sites in mice by immunohistochemistry. CD271-selected MSCs migrated toward the medium contained stem cell-derived factor-1 in vitro.

English

Powered by Koha